MDM2 and neutropenia: However, MDM2 inhibitors are mostly effective only in p53WT tumors, and they have been shown to induce thrombocytopenia, neutropenia, and other toxicities, though several recent clinical trials continue to ‘fine-tune’ these inhibitors and combine them with other appropriate therapies for further clinical development (33–36).